专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090087479A1 Orally bioavailable lipid-based constructs 有权
标题翻译：口服生物可利用的基于脂质的构建体
公开(公告)号：US20090087479A1
公开(公告)日：2009-04-02
申请号：US11904937
申请日：2007-09-28
申请人： John R. Lau , W. Blair Geho
发明人： John R. Lau , W. Blair Geho
IPC分类号： A61K9/127 , A61K38/28 , A61P3/00
CPC分类号： A61K9/127 , A61K9/1277 , A61K31/4045 , A61K38/21 , A61K38/23 , A61K38/28 , A61K47/24
摘要： The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapetucic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.
摘要翻译：本发明通过能够通过消化道的环境与典型的非口服可用的治疗剂或诊断剂分娩使得治疗药物或诊断剂是生物可利用的组合物来实现的。组合物可以或不可以靶向特定的细胞受体，例如肝细胞。治疗剂包括但不限于胰岛素，降钙素，5-羟色胺和其它蛋白质。用生物素或金属靶向剂完成靶向。

2. 发明授权

US06177099B1 Masking of liposomes from RES recognition 失效
标题翻译：从RES识别中掩盖脂质体
公开(公告)号：US06177099B1
公开(公告)日：2001-01-23
申请号：US08922799
申请日：1997-09-03
申请人： John R. Lau , W. Blair Geho
发明人： John R. Lau , W. Blair Geho
IPC分类号： A61K9127
CPC分类号： A61K9/1271 , Y10S436/829 , Y10T428/2984
摘要： A biochemical membrane encapsulated by neuraminic acid residue to mask the surface of the membrane from recognition and removal by the scavenging RES cells of the body.
摘要翻译：由神经氨酸残基包裹的生化膜可以通过身体的清除RES细胞来识别和去除膜的表面。

3. 发明授权

US4740375A Gelcores 失效
标题翻译：凝胶
公开(公告)号：US4740375A
公开(公告)日：1988-04-26
申请号：US705023
申请日：1985-02-25
申请人： W. Blair Geho , John R. Lau
发明人： W. Blair Geho , John R. Lau
IPC分类号： A61K9/127 , A61K9/50
CPC分类号： A61K9/1277 , Y10S514/801 , Y10S514/963 , Y10S514/965
摘要： This disclosure recognizes the fact that the technology of making vesicles from lecithin and lecithin-like molecules, although well known and highly developed, is associated with problems of instability. It is known that vesicles coalesce, rupture and spill their contents long before the vesicle is used for its intended purpose.It has been discovered and disclosed herein that the deterioration of the vesicle delivery system is due in part to the rupture of the bipolar lipid vesicle membrane by the contents of the core volume or by an external agent. For example, the more detergent-like the properties of the pharmacological agent within the vesicle core volume, the more pronounced will be the attack on the vesicle wall interior. These events in turn will lead to vesicle membrane rupture.This disclosure sets forth the proper manufacturing techniques to achieve vesicle stability following the discovery and also discloses a large-scale experiment which fully establishes the function taking place microscopically in the true vesicle. The experiment designed to substantiate the discovery is one using visible sized dialysis bags to show that gelatinized pharmacological agents are capable of existing without disruption in the appropriate solutions. The dialysis bag could not be used in the administration of a pharmacological agent to a person but illustrates on a large-scale what takes place microscopically in the actual vesicle environment.
摘要翻译：该公开内容认识到，虽然众所周知且高度发达的卵磷脂和卵磷脂样分子的制造泡囊的技术与不稳定性的问题相关联。众所周知，泡囊在使用囊泡的预期目的之前长时间聚结，破裂并溢出其内容物。本文已经发现和公开了囊泡递送系统的恶化部分是由于双相脂质囊泡膜由核心体积的内容物或外部剂量的破坏引起的。例如，洗涤剂类似于囊泡体积内的药剂的性质，对泡囊壁内部的攻击将更为显着。这些事件又会导致囊泡膜破裂。本公开阐述了在发现之后实现囊泡稳定性的适当制造技术，并且还公开了一种大规模实验，其完全建立了在真实囊泡中显微镜下发挥的功能。设计用于证实发现的实验是使用可见尺寸的透析袋来显示胶凝化的药理学剂能够在适当的溶液中存在而不中断。透析袋不能用于向人施用药理剂，而是在实际的泡囊环境中显微镜显示出大量的透析袋。

4. 发明授权

US4602043A Treatment for hypoglycemia 失效
标题翻译：低血糖治疗
公开(公告)号：US4602043A
公开(公告)日：1986-07-22
申请号：US604154
申请日：1984-04-26
申请人： W. Blair Geho
发明人： W. Blair Geho
IPC分类号： A61K31/445 , A61K31/135
CPC分类号： A61K31/445
摘要： This invention is for an improved method of treating the disease of hypoglycemia (low blood glucose), based on the discovery by the inventor of the etiology of the disease. The genesis of this invention is in the discovery that insulin alone does not control the uptake and regeneration of glucose by the liver. It has been discovered that hepatic storage of glucose following a meal requires the related function of insulin and serotonin. Hypoglycemia occurs during fasting and is due to an inappropriate release of serotonin to the liver. From this, the method of using a serotonin antagonist or an agent to block synthesis and/or storage of serotonin in timed relationship to ingested food to stop the action or the production of serotonin after glucose is no longer supplied to the portal vein is described. Then the liver can cease glucose uptake and begin production of glucose for the peripheral blood supply. The preferred antagonist is cyproheptadine.
摘要翻译：本发明是基于发明人发现病因病的治疗低血糖（低血糖）疾病的改进方法。本发明的起源在于发现单独的胰岛素不能控制肝脏对葡萄糖的摄取和再生。已经发现，膳食后的葡萄糖储存需要胰岛素和5-羟色胺的相关功能。低血糖发生在禁食期间，是由于5-羟色胺不适当地释放到肝脏。由此，描述了使用5-羟色胺拮抗剂或试剂阻止与摄入的食物的定时关系的合成和/或储存以停止葡萄糖后葡萄糖的血清素的作用或产生的方法不再提供给门静脉的方法。然后肝脏可以停止葡萄糖摄取，并开始生产葡萄糖用于外周血液供应。优选的拮抗剂是赛庚啶。

5. 发明授权

US07871641B2 Hepatocyte-targeting vehicle for delivery of glargine insulin to a mammal 有权
标题翻译：用于向哺乳动物递送甘精胰岛素的肝细胞靶向载体
公开(公告)号：US07871641B2
公开(公告)日：2011-01-18
申请号：US11384728
申请日：2006-03-20
申请人： John R. Lau , W. Blair Geho
发明人： John R. Lau , W. Blair Geho
IPC分类号： A61K9/127
CPC分类号： A61K9/1271 , A61K38/28
摘要： The instant invention is drawn to a hepatocyte targeted composition comprising a mixture of free glargine insulin and glargine insulin associated with a water insoluble target molecule complex, wherein the complex comprises multiple linked individual units and a supra-molecular lipid construct matrix. Glargine insulin is present within the complex in at least one form wherein the glargine insulin has a positive charge which interacts with a negative charge on the complex. The invention also includes methods for the manufacture of the composition and methods of managing blood glucose levels in individuals with Type I and Type II diabetes.
摘要翻译：本发明涉及包含与水不溶性靶分子复合物相关的甘精胰岛素和甘精胰岛素的混合物的肝细胞靶向组合物，其中所述复合物包含多个连接的单个单元和超分子脂质构建体基质。甘精胰岛素以至少一种形式存在于复合物内，其中甘精胰岛素具有与复合物上的负电荷相互作用的正电荷。本发明还包括用于制备I型和II型糖尿病个体的血糖水平组合物和方法的方法。

6. 发明申请

US20100247625A1 Orally Bioavailable Lipid-Based Constructs 有权
标题翻译：口腔生物可利用的脂质结构
公开(公告)号：US20100247625A1
公开(公告)日：2010-09-30
申请号：US12732952
申请日：2010-03-26
申请人： W. Blair Geho , John R. Lau
发明人： W. Blair Geho , John R. Lau
IPC分类号： A61K9/127 , A61P3/04 , A61P3/02 , A61K38/28 , A61K31/4188 , A61K39/44 , A61K31/4045 , A61K38/23 , A61P5/22 , A61K38/26 , A61K31/198 , A61K38/21 , A61P3/10 , A61P31/14 , A61P3/06 , A23L1/303
CPC分类号： C07K16/00 , A23L33/10 , A23L33/15 , A23L33/17 , A61K9/1272 , A61K9/4858 , A61K31/198 , A61K31/4045 , A61K31/4188 , A61K38/39 , A61K47/544 , A61K2039/505 , A61K2039/542 , A61K2300/00
摘要： The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof.
摘要翻译：本发明通过能够在有需要的患者中引起体重减轻的组合物来实现。

7. 发明授权

US4722937A Antitoxin vaginal products and catamenials 失效
标题翻译：抗生素阴道产品和月经期
公开(公告)号：US4722937A
公开(公告)日：1988-02-02
申请号：US819293
申请日：1986-01-16
申请人： Joseph Jacob , John R. Lau , W. Blair Geho
发明人： Joseph Jacob , John R. Lau , W. Blair Geho
IPC分类号： A61K9/00 , A61K31/375 , A61L15/20 , A61K31/34 , A61F13/20 , A61K9/70 , A61K31/19
CPC分类号： A61K31/375 , A61K9/0036 , A61L15/20 , Y10S514/841 , Y10S514/843 , Y10S514/921 , Y10S514/967 , Y10S514/968 , Y10S514/969
摘要： A method of prophylactics with respect to detoxification of Staphylococcus aureus and other toxins by ascorbic acid, salts and esters, topically applied by means of carriers which are otherwise regularly employed in the area where Staphylococcus aureus or other bacteria colonize, such as a pharmacological appliance including gauze pads, an absorbant mass or pad associated with menses, douches, and contraceptive compositions.
摘要翻译：关于金黄色葡萄球菌和其它毒素通过抗坏血酸，盐和酯进行解毒的预防药物的方法，其通过在金黄色葡萄球菌或其他细菌定居的区域中常规使用的载体局部施用，例如药理学器具，包括纱布垫，与月经，饮料和避孕组合物相关的吸收剂块或垫。

8. 发明授权

US08846053B2 Orally bioavailable lipid-based constructs 有权
标题翻译：口服生物可利用的基于脂质的构建体
公开(公告)号：US08846053B2
公开(公告)日：2014-09-30
申请号：US12816009
申请日：2010-06-15
申请人： W. Blair Geho , John R. Lau
发明人： W. Blair Geho , John R. Lau
IPC分类号： A61K36/00 , A61K36/82 , A61K36/33
CPC分类号： A61K47/28 , A23L33/10 , A23V2002/00 , A61K9/127 , A61K9/4858 , A61K31/198 , A61K31/4045 , A61K31/4188 , A61K47/24 , A61K47/544 , A61K47/557 , A61K2039/505 , A61K2039/542 , C07K16/00 , A23V2200/332 , A23V2250/72 , A23V2250/5432 , A23V2200/3262
摘要： The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof.
摘要翻译：本发明通过能够在有需要的患者中引起体重减轻的组合物来实现。

9. 发明授权

US08303983B2 Targeted liposomal drug delivery system 有权
标题翻译：靶向脂质体药物递送系统
公开(公告)号：US08303983B2
公开(公告)日：2012-11-06
申请号：US12687843
申请日：2010-01-14
申请人： John R. Lau , W. Blair Geho , George H. Snedeker
发明人： John R. Lau , W. Blair Geho , George H. Snedeker
IPC分类号： A61K9/127
CPC分类号： A61K9/1271 , A61K38/28
摘要： A metal targeting complex which associates with a charged liposomal structure is provided. The metal targeting complex provides the targetability of the liposomal construct to the desired receptor sites of a warm-blooded host for therapy or diagnostic use.
摘要翻译：提供了与带电脂质体结构相关联的金属靶向复合物。金属靶向复合物将脂质体构建体的靶向性提供给用于治疗或诊断用途的温血动物宿主的所需受体位点。

10. 发明授权

US08257735B2 Method of increasing the bioavailability of recombinant human insulin isophane in a patient 有权
标题翻译：增加患者重组人胰岛素分子体生物利用度的方法
公开(公告)号：US08257735B2
公开(公告)日：2012-09-04
申请号：US12953013
申请日：2010-11-23
申请人： John R. Lau , W. Blair Geho
发明人： John R. Lau , W. Blair Geho
IPC分类号： A61K9/127
CPC分类号： A61K49/1812 , A61K9/1271
摘要： The instant invention is drawn to a hepatocyte targeted composition comprising a mixture of free recombinant human insulin isophane and free Recombinant human regular insulin insulin and a mixture of recombinant human insulin isophane and Recombinant human regular insulin insulin associated with a water insoluble target molecule complex, wherein the complex comprises multiple linked individual units and a supra-molecular lipid construct matrix. Recombinant human insulin isophane and Recombinant human regular insulin insulin are present within the complex in at least one form wherein the recombinant human insulin isophane and Recombinant human regular insulin insulin have regions of positive charge which interacts with a negative charge on the complex. The invention also includes methods for the manufacture of the composition and methods of managing blood glucose levels in individuals with Type I and Type II diabetes.
摘要翻译：本发明涉及一种肝细胞靶向组合物，其包含游离重组人胰岛素异
环烷和游离的重组人正常胰岛素胰岛素的混合物，以及与水不溶性靶分子复合体缔合的重组人胰岛素异
构体和重组人正常胰岛素胰岛素的混合物，其中复合物包含多个连接的单个单元和超分子脂质构建体基质。重组人胰岛素异环素和重组人正常胰岛素胰岛素以至少一种形式存在于复合物内，其中重组人胰岛素异环烷和重组人正常胰岛素胰岛素具有与复合物上的负电荷相互作用的正电荷区域。本发明还包括用于制备I型和II型糖尿病个体的血糖水平组合物和方法的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式